Dr Jonathan Milner speaks to Thomas Warner from Proactive London about why he believes shareholders should vote against Life Science Company Abcam's acquisition by Danaher.
Dr. Milner provides some context, before going on to criticise what he considers a subpar acquisition offer from Danaher, stating that it undervalued the business. He highlights that Abcam typically traded at a much higher EBITDA multiple and the offer from Danaher represented a negative premium, severely disadvantaging shareholders.
Milner also criticises the timing of the acquisition, stating that it is not an opportune period to sell a life science company, given the current market conditions.
He questions the motives and financial decision-making of the current management, expressing concerns about their focus on performance bonuses.
He advises investors to gather information, question the board, and consider whether the Danaher deal is in their best interest.
Milner says that his campaign aims to protect Abcam's value and the interests of its shareholders during this critical decision-making period.
*Proactive asked Abcam for comment. The company has yet to reply to that request.